Lixte Biotechnology Files Proxy Materials
Ticker: LIXT · Form: DEFA14A · Filed: Oct 28, 2025 · CIK: 1335105
| Field | Detail |
|---|---|
| Company | Lixte Biotechnology Holdings, INC. (LIXT) |
| Form Type | DEFA14A |
| Filed Date | Oct 28, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-filing, shareholder-meeting, corporate-governance
Related Tickers: LIXT
TL;DR
LIXT filed proxy docs, shareholder vote coming up.
AI Summary
Lixte Biotechnology Holdings, Inc. (LIXT) filed a Definitive Additional Materials (DEFA14A) on October 28, 2025. The filing concerns proxy materials, indicating a shareholder meeting or vote is upcoming. The company, previously known as SRKP 7 INC, is incorporated in Delaware and operates in the Pharmaceutical Preparations sector.
Why It Matters
This filing signals that Lixte Biotechnology is preparing for important shareholder decisions, which could impact the company's future direction and governance.
Risk Assessment
Risk Level: low — This filing is a routine proxy statement, not indicating immediate financial distress or significant operational changes.
Key Players & Entities
- LIXTE BIOTECHNOLOGY HOLDINGS, INC. (company) — Registrant
- SRKP 7 INC (company) — Former company name
- 20251028 (date) — Filing date
FAQ
What is the purpose of this DEFA14A filing?
This filing is a Definitive Additional Material (DEFA14A) related to proxy statements, indicating it contains materials for a shareholder meeting or vote.
When was this filing made?
The filing was made on October 28, 2025.
What is the company's primary business sector?
The company operates in the Pharmaceutical Preparations sector, with SIC code 2834.
Has the company always been known as Lixte Biotechnology Holdings, Inc.?
No, the company was formerly known as SRKP 7 INC, with a name change date of August 3, 2005.
Where is Lixte Biotechnology Holdings, Inc. incorporated?
The company is incorporated in Delaware (DE).
Filing Stats: 250 words · 1 min read · ~1 pages · Grade level 13.2 · Accepted 2025-10-28 16:25:07
Filing Documents
- formdefa14a.htm (DEFA14A) — 28KB
- proxy_001.jpg (GRAPHIC) — 431KB
- proxy_002.jpg (GRAPHIC) — 390KB
- 0001493152-25-019890.txt ( ) — 1160KB
From the Filing
UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy (Amendment No. __) Filed by the Registrant Filed by a party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material under §240.14a-12 LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Name of Registrant as Specified in Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): No fee required. Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. (1) Title of each class of securities to which transaction applies: (2) Aggregate number of securities to which transaction applies: (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): (4) Proposed maximum aggregate value of transaction: (5) Total fee paid: Fee paid previously with preliminary materials. Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. (1) Amount Previously Paid: (2) Form, Schedule or Registration Statement No.: (3) Filing Party: (4) Date Filed: